ReViral welcomes Dr Jason Zhou to its Board and raises $44m Series C financing led by CR-CP Life Science Fund

– UK, Stevenage –  ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus, today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund alongside other investors participating including Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors.

Concurrent with the financing, Dr Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joins the ReViral Board of Directors.

“We are pleased to invest in ReViral and support their work to develop and commercialize novel therapeutics to treat RSV, a major global health concern. We have confidence that ReViral’s world class management team, strong science, and deep clinical expertise will enable ReViral to become a leader in the RSV market.” said Dr. Zhou.

“We are delighted by the strong financial support from this leading syndicate of healthcare investors, and we welcome Jason to our Board”, said CEO, Alex Sapir. “The proceeds from the financing will be used to support Phase 2 clinical development for sisunatovir, our wholly-owned fusion protein inhibitor, and to progress our N-protein replication inhibitor program into Phase 1.”

About ReViral

ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of the respiratory syncytial virus. The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a pediatric patient population and the other in an adult stem-cell transplant patient population. In addition, the company has an N-protein replication inhibitor program in late preclinical development. Both programs were discovered in-house and the company has retained worldwide development and commercialization rights.

For more information: https://reviral.co.uk/

About CR-CP Life Science Fund

CR-CP Life Science Fund is a venture capital fund jointly sponsored by China Resources Group and Charoen Pokphand Group with initial AUM of $300 million contributed by CR, CP and other global life science investors. The Fund invests in leading life science companies that develop innovative drugs, cell therapies, medical devices and smart healthcare technologies.

About Sisunatovir

Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Sisunatovir was recently granted Fast Track designation by the U.S. Food and Drug Administration. Preclinical tests demonstrated sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir achieved target exposure levels with no serious adverse events being reported. In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported, in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has recently initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.